High or low doses of ACE inhibitors for heart failure?
Results of the ATLAS study
Robert E. Hobbs, MD
Section of Heart Failure/Transplant, Department of Cardiology, Cleveland Clinic
Address: Robert E. Hobbs, MD, Department of Cardiology, F25, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195
In a large, randomized study, patients with heart failure who received a large daily dose of an angiotensin-converting inhibitor had a trend toward a lower mortality rate than did patients who received a low daily dose. Moreover, the hospitalization rate was lower in the high-dose group, and the side-effect profile was the same in both groups. Physicians should try to give maximal closes to achieve optimum benefit in this patient population.